June 14, 2017 10:10 AM EDT
R&D

Epizyme shares slump as can­cer drug da­ta up­date dis­ap­points

John Carroll

Editor & Founder

An­a­lysts hate to be dis­ap­point­ed, and that’s just what Epizyme $EPZM ac­com­plished this morn­ing as it up­dat­ed its camp fol­low­ers with the lat­est

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ideaya inks ADC deal with $75M up­front; Amy­lyx, Gubra to de­vel­op long-act­ing GLP-1

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

A service from the Financial Times